Privium Fund Management B.V. Ultragenyx Pharmaceutical Inc. Transaction History
Privium Fund Management B.V.
- $354 Million
- Q2 2024
A detailed history of Privium Fund Management B.V. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 251,602 shares of RARE stock, worth $13.3 Million. This represents 2.92% of its overall portfolio holdings.
Number of Shares
251,602
Previous 215,102
16.97%
Holding current value
$13.3 Million
Previous $10 Million
2.96%
% of portfolio
2.92%
Previous 2.97%
Shares
11 transactions
Others Institutions Holding RARE
# of Institutions
288Shares Held
88.2MCall Options Held
505KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$516 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$296 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$283 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$241 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$172 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.7B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...